| Literature DB >> 7974891 |
Abstract
Salvage therapy is not readily available to patients with recurrent renal cell carcinoma. Selected solitary metastases may be resected, a tumor on the contralateral kidney may be excised, or the patient may be amenable to systemic biologic response modifier therapy. More commonly, only palliative therapy is available, and follow-up is tailored with the former considerations in mind. Early investigation of symptoms may minimize later morbidity from metastases to the brain or bone. A proposed follow-up schedule is presented.Entities:
Mesh:
Year: 1994 PMID: 7974891
Source DB: PubMed Journal: Urol Clin North Am ISSN: 0094-0143 Impact factor: 2.241